Pharmaceuticals
J&J tops first-quarter profit estimates even as Stelara sales plunge
Johnson & Johnson beat first-quarter earnings expectations on Tuesday and raised its full-year forecast, as strong demand for cancer drug Darzalex and psoriasis treatment Tremfya more than offset a steep falloff in sales of its blockbuster autoimmune drug Stelara. And the company expressed confidence in its just-approved once-daily, oral psoriasis treatment, Icotyde, saying about 1,500 […]
Read More
Novo Nordisk partners with OpenAI as AI drug discovery hopes mount
People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in Copenhagen, Denmark, March 26, 2026. Tom Little | Reuters Novo Nordisk is partnering with OpenAI to “bring new and better treatment options to patients faster,” the Danish drugmaker said Tuesday. The partnership will enable Novo to better […]
Read More
Jim Cramer says this is the real reason why stocks are shrugging off Iran war fears
CNBC’s Jim Cramer said Monday that Wall Street’s resilience in the face of escalating geopolitical tensions shows investors are focusing less on the Iran war itself and more on a key driver of stock valuations: interest rates. “I think I’ve been negligent in bringing up the power of low rates, because it’s the reason the […]
Read More
Trump policies, China’s biotech boom are ending Europe’s pharma powerhouse era
Boxes of medication are seen on the shelves of the Keencare pharmacy, a member of the Green Light Group, on September 19, 2024 in London, England. Leon Neal | Getty Images News | Getty Images Once the go-to location for global drugmakers, Europe is now being squeezed by President Donald Trump’s aggressive trade and drug-pricing […]
Read More
Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters The market share of India’s most popular weight‑loss drugmaker, Eli Lilly, slipped in March, while rival Novo Nordisk held steady even as Indian generic drugmakers flooded the market with lower‑priced copies. Eli Lilly’s Indian market share in the GLP‑1 category of […]
Read More
Novo Nordisk’s explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
After years of trying to lose weight “the right way,” Jane Zuckerman realized that “putting in the work just wasn’t enough.” Zuckerman, a 32-year-old data analyst based in Washington, D.C., said she lost 90 pounds in college and spent years cycling through nutritionists, therapy and strict routines — only to find herself at her heaviest […]
Read More
Trump tariff fallout: Some industries grapple with lingering effects one year later
A year after President Donald Trump declared his “liberation day” and imposed sweeping tariffs on imports, kicking off a wave of economic and political uncertainty, some companies are still feeling the effects. While some industries have emerged largely unscathed — having weathered twists and turns of several tariff iterations — others, such as retail, automotive, […]
Read More
Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
The Trump administration is preparing to impose new tariffs on branded drugs from pharmaceutical companies that have not struck landmark deals with the president to lower their U.S. drug prices, CNBC has learned. Patented medications and their active ingredients would be hit with a 100% tariff, according to a draft of the document obtained by […]
Read More
Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
Wegovy semaglutide tablets. Michael Siluk | Universal Images Group | Getty Images The Wegovy pill showed more pronounced weight loss and less cumbersome side effects than Eli Lilly‘s rival pill that was approved this week, Novo Nordisk said Thursday. Oral Wegovy demonstrated “significantly greater mean weight loss” than orforglipron, which Lilly will sell under the […]
Read More
Novo Nordisk shares rise after Wegovy recommended by Britain’s drug price regulator
Michael Siluk | UCG | Universal Images Group | Getty Images Novo Nordisk rose as much as 4% after England’s drug price regulator recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes. Wegovy is mainly a weight loss treatment but it is also approved for reducing the risk of major […]
Read More